Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00035880
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2002-05-06
Brief Title:
Study Comparing ABX-CBL Monoclonal Antibody Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease
Sponsor:
Abgenix
Organization:
Abgenix
Study Overview
Official Title:
A Phase IIIII Multicenter Open Label Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease
Status:
COMPLETED
Status Verified Date:
2003-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Trial evaluating the improvement in survival at 180 days of two therapies Atgam versus ABX-CBL a monoclonal antibody in patients with acute graft versus host disease that does not respond to steroid therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None